$7.20
0.14[1.98%]
At close: May 21
$7.20
0[0.00%]
After Hours: 6:22PM EDT
Humacyte
(NASDAQ:HUMA)Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions
Humacyte Inc has a consensus price target of $9.75, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from Benchmark, Cantor Fitzgerald, and Piper Sandler on May 13, 2024, April 1, 2024, and March 26, 2024. With an average price target of $8.67 between Benchmark, Cantor Fitzgerald, and Piper Sandler, there's an implied 20.37% upside for Humacyte Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Cantor Fitzgerald
Piper Sandler
HC Wainwright & Co.
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Humacyte
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 108.33% | Benchmark | Bruce Jackson | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | Buy Now | -2.78% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 03/26/2024 | Buy Now | -44.44% | Piper Sandler | Allison Bratzel | $4 → $4 | Maintains | Neutral | Get Alert |
| 03/25/2024 | Buy Now | 108.33% | Benchmark | Bruce Jackson | → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | -44.44% | Piper Sandler | Allison Bratzel | $3 → $4 | Maintains | Neutral | Get Alert |
| 12/27/2023 | Buy Now | 108.33% | Benchmark | Bruce Jackson | $16 → $15 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | -16.67% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Initiates | → Buy | Get Alert |
| 11/10/2023 | Buy Now | -58.33% | Piper Sandler | Matt O'Brien | $3.5 → $3 | Maintains | Neutral | Get Alert |
| 09/21/2023 | Buy Now | -2.78% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 08/31/2023 | Buy Now | -16.67% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/24/2023 | Buy Now | -16.67% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 122.22% | Benchmark | Bruce Jackson | → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | -16.67% | Cantor Fitzgerald | Kristen Kluska | → $6 | Initiates | → Overweight | Get Alert |
| 06/12/2023 | Buy Now | 122.22% | Benchmark | Bruce Jackson | → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2023 | Buy Now | 122.22% | Benchmark | Bruce Jackson | → $16 | Reiterates | → Buy | Get Alert |
| 07/18/2022 | Buy Now | 38.89% | BTIG | Ryan Zimmerman | $12 → $10 | Maintains | Buy | Get Alert |
| 10/29/2021 | Buy Now | 136.11% | Cowen & Co. | Joshua Jennings | — | Initiates | → Outperform | Get Alert |
| 09/24/2021 | Buy Now | 122.22% | Oppenheimer | Suraj Kalia | — | Initiates | → Outperform | Get Alert |
| 09/22/2021 | Buy Now | 163.89% | BTIG | Ryan Zimmerman | — | Initiates | → Buy | Get Alert |
| 09/16/2021 | Buy Now | 136.11% | Piper Sandler | Matt O'Brien | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Humacyte (HUMA)?
The latest price target for Humacyte (NASDAQ: HUMA) was reported by Benchmark on May 13, 2024. The analyst firm set a price target for $15.00 expecting HUMA to rise to within 12 months (a possible 108.33% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Humacyte (HUMA)?
The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Benchmark, and Humacyte reiterated their buy rating.
When was the last upgrade for Humacyte (HUMA)?
There is no last upgrade for Humacyte.
When was the last downgrade for Humacyte (HUMA)?
There is no last downgrade for Humacyte.
When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating Humacyte (HUMA) correct?
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $15.00. The current price Humacyte (HUMA) is trading at is $7.20, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.